Viatris Inc at Citi BioPharma Conference (Virtual) Transcript

Sep 10, 2021 / 03:35PM GMT
Navann Ty - Citigroup Inc., Research Division - Director

Hi. Good morning, everyone. This is Navann Ty. I cover spec pharma at Citi, including Viatris. So Viatris is the combination of Mylan and Pfizer spin-off Upjohn business. And today, I have the pleasure of having with me Michael Goettler, who's the CEO of Viatris; Rajiv Malik, the President; and Bill Szablewski, the Head of Capital Markets.

So before I start the Q&A, I'll just hand over to Bill for forward-looking statement.

William Szablewski - Viatris Inc. - Head of Capital Markets

Yes. Thank you, Navann, and good morning, everybody. During today's discussion, we may make forward-looking statements on a number of matters. These forward-looking statements are subject to risks and uncertainty that could cause future results or events to differ materially from today's projections and discussion. Please refer to our SEC filings for a fuller explanation of those risks and uncertainties and the limits applicable to the forward-looking statements. Also, during today's discussion, we will not be

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot